BackClinuvel Pharmaceuticals Limited Overview

Clinuvel Pharmaceuticals Limited Current Cash

Latest current cash for CLVLY: $36M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$36.10M
↑ 114.63% YoYΔ $19.28M vs prior year quarter

Peer trimmed avg / median

Loading

Clinuvel Pharmaceuticals Limited Current Cash History

Loading

Clinuvel Pharmaceuticals Limited vs. peers: Current Cash Comparison

Loading

Clinuvel Pharmaceuticals Limited Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Clinuvel Pharmaceuticals Limited (CLVLY) FAQ

Clinuvel Pharmaceuticals Limited's current cash stands at $36M as of December 2025. That compares with $17M in the prior-year period — up 114.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Clinuvel Pharmaceuticals Limited reported $36M in current cash versus $17M a year earlier — a 114.6% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $17M in the prior-year period — up 114.6% year over year. Sustained growth in current cash can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Clinuvel Pharmaceuticals Limited's current cash evolved across reporting periods, while the comparison chart places CLVLY next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current cash is commonly used to spot outliers. Clinuvel Pharmaceuticals Limited's reading of $36M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.